Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | GRM5 | P41594 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28751450 | 0.83 | KCNH2 (0.51) | RAB9ASMN1; SMN2GRM5ALDH1A1GRM4 | |
| SCHEMBL6313746 | 0.83 | CA12 (0.47) | RAB9ACA12CA1CA2CA9 | |
| SCHEMBL6314495 | 0.78 | KCNH2 (0.53) | CA12CA1CA2CA9GRM5 | |
| SCHEMBL2249460 | 0.77 | SMN1; SMN2 (0.49) | NPC1RAB9ASMN1; SMN2ALDH1A1NFE2L2 | |
| SCHEMBL31286312 | 0.76 | CA12 (0.62) | CA12CA1CA2CA9GRM5 | |
| SCHEMBL9302636 | 0.76 | CA12 (0.62) | CA12CA1CA2CA9GRM5 | |
| SCHEMBL8865572 | 0.75 | ALDH1A1 (0.44) | NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4713235 | 0.73 | GRM5 (0.68) | GRM5SLC6A2 | |
| SCHEMBL6787407 | 0.73 | GRM5 (0.63) | NPC1RAB9ASMN1; SMN2GRM5ALDH1A1 | |
| SCHEMBL9304700 | 0.73 | CA12 (0.62) | CA12CA1CA2CA9GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1608065-A | Phenyl substituted triazoles and their use as selective inhibors of akl5 kinase and pharmaceutical compositions containing the compounds | SMITHKLINE BEECHAM CORP (US) | 2005-04-20 | — | — | CN | disclosed |
| US-20050014938-A1 | Phenyl substituted triazoles and their use as selective inhibitors of akl5 kinase | GASTER LARAMIE MARY (GB) | 2005-01-20 | — | — | US | disclosed |
| EP-1444232-A1 | PHENYL SUBSTITUTED TRIAZOLES AND THEIR USE AS SELECTIVE INHIBORS OF AKL5 KINASE | SMITHKLINE BEECHAM CORPORATION (US) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003042211-A1 | PHENYL SUBSTITUTED TRIAZOLES AND THEIR USE AS SELECTIVE INHIBORS OF AKL5 KINASE | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014938-A1 | Phenyl substituted triazoles and their use as selective inhibitors of akl5 kinase | AKR1C3, CBR3, PHKG1 | NPC1 1967/4885RAB9A 3422/4885SMN1; SMN2 4792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.